Targeted Treatment in Colorectal Cancer: New Mechanisms and Agents and the Role of Clinical Trials in Practice

Select Publications

MARSHALL


De Gramont A et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc ASCO 2007;Abstract 4007.


I-SPY 2 TRIAL: Neoadjuvant and personalized adaptive novel agents to treat breast cancer. NCT01042379


HECHT

Cassidy J et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Proc ESMO 2006;Abstract LBA3.


Hecht JR et al. Sunitinib plus 5-flourouracil, leucovorin and oxaliplatin (mFOLFOX6) vs bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer (MCRC) — Interim results of a randomized, Phase IIB study. 12th ESMO World Congress on Gastrointestinal Cancer 2010;Abstract 0-0014.


Van Cutsem E et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR). 13th ESMO World Congress on Gastrointestinal Cancer 2011;Abstract 0-0024.
ARNOLD


Tabernero J et al. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. European Multidisciplinary Congress 2011;Abstract 6LBA.


ENG


Bessudo A et al. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. Proc ASCO 2011;Abstract 3582.


Eng C et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. Proc ASCO 2011;Abstract 3500.


FISHER

Allegra CJ et al. Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. Proc ASCO 2011;Abstract 3508.


Andre T et al. A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. Proc ASCO 2011;Abstract 3509.


Tsimberidou AM et al. **Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative.** *Proc ASCO* 2011; Abstract CRA2500.

Wolmark N et al. **A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP protocol C-08.** *Proc ASCO* 2009; Abstract LBA4.